RxDoctor Payments Data

Raymond Miller, MD

Clinical Cardiac Electrophysiology · Dover, DENPI 1205802188

Payments from drug & device makers

$8,697in general payments, 2019–2025

Across 326 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$1K
  • Novartis$519
  • Boston Scientific$387
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$341
  • E.r. Squibb & Sons, L.L.C.$324
  • plus $740 from 14 others

What the payments were for

  • Travel & lodging$1,63219%
  • Food & beverage$7,03881%
  • Other$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$477,516
Medicare patients
2,117
Services billed
8,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$94,841
XareltoRivaroxaban34$45,303
JardianceEmpagliflozin44$40,594
EntrestoSacubitril/Valsartan27$37,176
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$3,516
Metoprolol Succinate182$2,969
Rosuvastatin Calcium65$2,282
Atorvastatin Calcium93$1,461
Digoxin40$1,091
Losartan Potassium115$1,069
Ezetimibe26$1,066
Hydralazine Hcl55$987
Amiodarone Hcl42$968
Metoprolol Tartrate62$863
Midodrine Hcl12$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$94,84180 claims
Johnson & JohnsonXarelto$50$45,30334 claims
NovartisEntresto$519$37,17627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Dover

Where these figures come from

Is this you, or does something look wrong? →